Active	Status	Sponsor type	Region	Phase	Filter
3 Active 6 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Larson, Richard A
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)	Active, not recruiting	2	104	Europe, Canada, US, RoW	Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent	Novartis Pharmaceuticals	CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases	11/21	02/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Active, not recruiting	2	196	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	09/25	10/27
NCT05925920: Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes	Active, not recruiting	1	49	US	ENT-03, Placebo	Metabolics Pharma	Obesity, Diabetes Mellitus, Type 2	08/24	12/24
Murray, Judith
No trials found